Clinical Trial

Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer

Study acronym: TAORMINA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 21, 2022 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy (investigational arm) versus systemic therapy alone (control arm) as 1st line therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-05-11.
Status change: Not Yet Recruiting → Recruiting 2022-10-18
Trial Details
NCT Number NCT05377047
Lead Sponsor Vastra Gotaland Region
Collaborators: Sahlgrenska University Hospital, Azienda Ospedaliero-Universitaria Careggi, Region Örebro County, Skane University Hospital, Uppsala University Hospital, Karolinska University Hospital, University Hospital, Umeå, Sundsvall Hospital, Karlstad Central Hospital, Gävle Hospital, Centrallasarettet Västerås, Oslo University Hospital, St. Olavs Hospital, Haukeland University Hospital, University of Stavanger, University Hospital of North Norway
Conditions Breast Cancer Stage IV, Oligometastatic Disease
Enrollment 345 participants
Start Date 2022-09-19
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2022-10-21